Efficiency of Using Antiinflammatory Drug with Antileukotriene Action — Montelukast Sodium as a Mean of Controlled Therapy of Bronchial Asthma and Allergic Rhinitis in Children

• Main Author: O.M. Оkhotnikova
• Format: Article
• Language: English
• Published: Publishing House Zaslavsky 2016-05-01
• Series: Zdorovʹe Rebenka
• Subjects: antagonists of cysteinil-leukotriene receptors; montelukast sodium; bronchial asthma; allergic rhinitis; children aged 2–11 years
• Online Access: http://childshealth.zaslavsky.com.ua/article/view/76585
• ISSN: 2224-0551; 2307-1168

The article presents modern approaches to the problem of bronchial asthma and allergic rhinitis as comorbid pathology in children. We have considered the concept of a single chronic allergic respiratory syndrome. According to international and national guidelines for the management of patients with bronchial asthma and allergic rhinitis, the place of antileukotrienes was determined in the treatment of this comorbidity. The data on the compliance when treating children with bronchial asthma and ways to optimize it are presented. Scientific substantiation is provided for the use of montelukast sodium in the general basic treatment of persistent mild forms of allergic rhinitis and bronchial asthma in children. The article presents the results of using antileukotriene drug montelukast sodium in the controlled treatment of persistent mild forms of bronchial asthma and allergic rhinitis in children aged 2–11 years. The results of our investigation proved that the 6-month use of the drug is highly effective (95.0 %) that provides control of the disease. Montelukast is particularly indicated in the prevalence of nocturnal symptoms of the disease, in cases of asthma with physical and emotional stress, aspirin-induced asthma, exacerbations of the disease, caused by changes in weather conditions and by viral infections.